Hutchmed (HCM) announced that the new drug application for fanregratinib for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusion/rearrangement who have previously received systemic therapy has been accepted and granted priority review by the China National Medical Products Administration.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCM: